DDInter1704 DDInter596
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376]
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} (Compound) causes {v} (Side Effect) Hyperlipidaemia
Hyperlipidaemia {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} (Compound) causes {v} (Side Effect) Hyperlipidaemia
Hyperlipidaemia {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} (Compound) resembles {v} (Compound) Atenolol
Atenolol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Sotalol may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Sotalol may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Sotalol (Compound) causes Hyperlipidaemia (Side Effect) and Hyperlipidaemia (Side Effect) is caused by Doxorubicin (Compound)
Sotalol may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Sotalol may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Sotalol may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Sotalol (Compound) causes Hyperlipidaemia (Side Effect) and Hyperlipidaemia (Side Effect) is caused by Epirubicin (Compound) and Epirubicin (Compound) resembles Doxorubicin (Compound)
Sotalol (Compound) resembles Atenolol (Compound) and Atenolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Sotalol may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Sotalol may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)